{"id":35224,"date":"2025-06-16T11:51:33","date_gmt":"2025-06-16T03:51:33","guid":{"rendered":"https:\/\/flcube.com\/?p=35224"},"modified":"2025-06-16T11:51:34","modified_gmt":"2025-06-16T03:51:34","slug":"cloudbreak-pharma-files-for-hong-kong-ipo-amid-ophthalmic-drug-development","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=35224","title":{"rendered":"Cloudbreak Pharma Files for Hong Kong IPO Amid Ophthalmic Drug Development"},"content":{"rendered":"\n<p>Cloudbreak Pharma Inc. has submitted another initial public offering (IPO) filing to the Hong Kong Stock Exchange this week, with CCB International and Huatai International acting as joint sponsors. The clinical-stage ophthalmic biotech firm specializes in the independent research and development of treatments for eye diseases. Cloudbreak established its first major operating entity in the United States in 2015 and was incorporated in the Cayman Islands in 2020.<\/p>\n\n\n\n<p><strong>Pipeline Highlights<\/strong><br>Cloudbreak&#8217;s pipeline includes two core candidates: CBT-001 and CBT-009. CBT-001 is undergoing multi-regional Phase III clinical trials in the US and China for pterygium. CBT-009, targeting myopia in children and adolescents (aged 5\u201319), completed Phase I\/II trials in 2023 and was filed for clinical study in the US in 2024. The company also has additional clinical-stage assets and four preclinical candidates.<\/p>\n\n\n\n<p><strong>Financial Overview<\/strong><br>In 2024, Cloudbreak reported revenue of approximately USD 10 million. R&amp;D expenditures stood at USD 37.95 million, with an annual net loss of USD 99.13 million. From 2022 to 2024, cumulative R&amp;D spending reached USD 84.53 million, underscoring the company&#8217;s commitment to advancing its therapeutic pipeline.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/sehk25061100779_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of sehk25061100779_c.\"><\/object><a id=\"wp-block-file--media-18a9d2e6-e4b7-47f8-a1c7-926fdece895e\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/sehk25061100779_c.pdf\">sehk25061100779_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/sehk25061100779_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-18a9d2e6-e4b7-47f8-a1c7-926fdece895e\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Cloudbreak Pharma Inc. has submitted another initial public offering (IPO) filing to the Hong Kong&#8230;<\/p>\n","protected":false},"author":1,"featured_media":35226,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[414,72,44],"class_list":["post-35224","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-cloudbreak-pharma","tag-ipo","tag-ophthalmology"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Cloudbreak Pharma Files for Hong Kong IPO Amid Ophthalmic Drug Development - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Cloudbreak Pharma Inc. has submitted another initial public offering (IPO) filing to the Hong Kong Stock Exchange this week, with CCB International and Huatai International acting as joint sponsors. The clinical-stage ophthalmic biotech firm specializes in the independent research and development of treatments for eye diseases. Cloudbreak established its first major operating entity in the United States in 2015 and was incorporated in the Cayman Islands in 2020.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=35224\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Cloudbreak Pharma Files for Hong Kong IPO Amid Ophthalmic Drug Development\" \/>\n<meta property=\"og:description\" content=\"Cloudbreak Pharma Inc. has submitted another initial public offering (IPO) filing to the Hong Kong Stock Exchange this week, with CCB International and Huatai International acting as joint sponsors. The clinical-stage ophthalmic biotech firm specializes in the independent research and development of treatments for eye diseases. Cloudbreak established its first major operating entity in the United States in 2015 and was incorporated in the Cayman Islands in 2020.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=35224\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-06-16T03:51:33+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-06-16T03:51:34+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/1601.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=35224#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=35224\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Cloudbreak Pharma Files for Hong Kong IPO Amid Ophthalmic Drug Development\",\"datePublished\":\"2025-06-16T03:51:33+00:00\",\"dateModified\":\"2025-06-16T03:51:34+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=35224\"},\"wordCount\":192,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=35224#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/1601.webp\",\"keywords\":[\"Cloudbreak Pharma\",\"IPO\",\"Ophthalmology\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=35224#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=35224\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=35224\",\"name\":\"Cloudbreak Pharma Files for Hong Kong IPO Amid Ophthalmic Drug Development - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=35224#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=35224#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/1601.webp\",\"datePublished\":\"2025-06-16T03:51:33+00:00\",\"dateModified\":\"2025-06-16T03:51:34+00:00\",\"description\":\"Cloudbreak Pharma Inc. has submitted another initial public offering (IPO) filing to the Hong Kong Stock Exchange this week, with CCB International and Huatai International acting as joint sponsors. The clinical-stage ophthalmic biotech firm specializes in the independent research and development of treatments for eye diseases. Cloudbreak established its first major operating entity in the United States in 2015 and was incorporated in the Cayman Islands in 2020.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=35224#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=35224\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=35224#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/1601.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/1601.webp\",\"width\":1080,\"height\":608,\"caption\":\"Cloudbreak Pharma Files for Hong Kong IPO Amid Ophthalmic Drug Development\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=35224#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Cloudbreak Pharma Files for Hong Kong IPO Amid Ophthalmic Drug Development\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Cloudbreak Pharma Files for Hong Kong IPO Amid Ophthalmic Drug Development - Insight, China&#039;s Pharmaceutical Industry","description":"Cloudbreak Pharma Inc. has submitted another initial public offering (IPO) filing to the Hong Kong Stock Exchange this week, with CCB International and Huatai International acting as joint sponsors. The clinical-stage ophthalmic biotech firm specializes in the independent research and development of treatments for eye diseases. Cloudbreak established its first major operating entity in the United States in 2015 and was incorporated in the Cayman Islands in 2020.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=35224","og_locale":"en_US","og_type":"article","og_title":"Cloudbreak Pharma Files for Hong Kong IPO Amid Ophthalmic Drug Development","og_description":"Cloudbreak Pharma Inc. has submitted another initial public offering (IPO) filing to the Hong Kong Stock Exchange this week, with CCB International and Huatai International acting as joint sponsors. The clinical-stage ophthalmic biotech firm specializes in the independent research and development of treatments for eye diseases. Cloudbreak established its first major operating entity in the United States in 2015 and was incorporated in the Cayman Islands in 2020.","og_url":"https:\/\/flcube.com\/?p=35224","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-06-16T03:51:33+00:00","article_modified_time":"2025-06-16T03:51:34+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/1601.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=35224#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=35224"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Cloudbreak Pharma Files for Hong Kong IPO Amid Ophthalmic Drug Development","datePublished":"2025-06-16T03:51:33+00:00","dateModified":"2025-06-16T03:51:34+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=35224"},"wordCount":192,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=35224#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/1601.webp","keywords":["Cloudbreak Pharma","IPO","Ophthalmology"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=35224#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=35224","url":"https:\/\/flcube.com\/?p=35224","name":"Cloudbreak Pharma Files for Hong Kong IPO Amid Ophthalmic Drug Development - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=35224#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=35224#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/1601.webp","datePublished":"2025-06-16T03:51:33+00:00","dateModified":"2025-06-16T03:51:34+00:00","description":"Cloudbreak Pharma Inc. has submitted another initial public offering (IPO) filing to the Hong Kong Stock Exchange this week, with CCB International and Huatai International acting as joint sponsors. The clinical-stage ophthalmic biotech firm specializes in the independent research and development of treatments for eye diseases. Cloudbreak established its first major operating entity in the United States in 2015 and was incorporated in the Cayman Islands in 2020.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=35224#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=35224"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=35224#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/1601.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/1601.webp","width":1080,"height":608,"caption":"Cloudbreak Pharma Files for Hong Kong IPO Amid Ophthalmic Drug Development"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=35224#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Cloudbreak Pharma Files for Hong Kong IPO Amid Ophthalmic Drug Development"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/1601.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/35224","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=35224"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/35224\/revisions"}],"predecessor-version":[{"id":35227,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/35224\/revisions\/35227"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/35226"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=35224"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=35224"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=35224"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}